HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

M 16287

structure given in first source

Also Known As:

1-(3-chlorobenzo(b)furan-2-ylsulfonyl)hydantoin; M-16287; M16287; 2,4-Imidazolidinedione, 1-((3-chloro-2-benzofuranyl)sulfonyl)-

Networked: 3 relevant articles (2 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Imidazoles: 150
      - Imidazolidines: 39
        Hydantoins: 306
        M 16287: 3
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Benzofurans: 26
      - M 16287: 3

Related Diseases

1.	Diabetes Complications 02/07/1991 - "The present study indicates that M16209 and M16287 are potent aldose reductase inhibitors expected to be useful for the treatment of diabetic complications." 06/01/1991 - "These results indicate that M16209 and M16287 are potent aldose reductase inhibitors, which could be applicable to treatment for diabetic complications." 12/01/1990 - "These results indicate that M16209 and M16287 can prevent galactose-induced cataract formation through amelioration of metabolic disorders and thus have high potential for clinical use in the treatment of some diabetic complications."
2.	Diabetic Neuropathies (Diabetic Neuropathy) 02/07/1991 - "Effects of novel aldose reductase inhibitors, M16209 and M16287, on streptozotocin-induced diabetic neuropathy in rats." 06/01/1991 - "M16209 and M16287 were effective in the prevention of galactosemic cataracts and amelioration of diabetic neuropathy with almost the same potency, while ONO-2235 was effective only in neuropathy, and sorbinil was effective in galactosemic cataracts and diabetic neuropathy with a different potency. "
3.	Cataract (Cataracts) 12/01/1990 - "These results indicate that M16209 and M16287 can prevent galactose-induced cataract formation through amelioration of metabolic disorders and thus have high potential for clinical use in the treatment of some diabetic complications." 06/01/1991 - "M16209 and M16287 were effective in the prevention of galactosemic cataracts and amelioration of diabetic neuropathy with almost the same potency, while ONO-2235 was effective only in neuropathy, and sorbinil was effective in galactosemic cataracts and diabetic neuropathy with a different potency. " 12/01/1990 - "Effects of novel aldose reductase inhibitors, M16209 (1-(3-bromobenzo[b]furan-2-ylsulfonyl)hydantoin) and M16287 (1-(3-chlorobenzo[b]furan-2-ylsulfonyl)hydantoin), on galactose-induced cataract formation in rats were investigated. "

Related Drugs and Biologics

1.	M 16209
2.	Aldehyde Reductase (Aldose Reductase)
3.	epalrestat
4.	sorbinil
5.	Streptozocin (Streptozotocin)
6.	Hydantoins
7.	Galactose (Galactopyranose)
8.	furan